160 results about "Direct Treatment" patented technology

A method for direct therapeutic treatment of myocardial tissue in a localized region of a heart having a pathological condition. The method includes identifying a target region of the myocardium and applying material directly and substantially only to at least a portion of the myocardial tissue of the target region. The material applied results in a physically modification the mechanical properties, including stiffness, of said tissue. Various devices and modes of practicing the method are disclosed for stiffening, restraining and constraining myocardial tissue for the treatment of conditions including myocardial infarction or mitral valve regurgitation.

The invention provides systems for automatically localizing areas of disease within a tissue sample using fluorescence spectra, reflectance spectra, and video images obtained from the sample. The invention further provides systems for displaying, marking, and treating the identified areas so that healthy surrounding tissue suffers minimal impact upon treatment and / or excision of the diseased tissue. The invention facilitates minimally-invasive treatment by accurately directing treatment to only those areas that are identified as diseased.

Partial or total occlusions of fluid passages within the human body are removed by positioning an array of optical fibers in the passage and directing treatment radiation pulses along the fibers, one at a time, to generate a shock wave and hydrodynamic flows that strike and emulsify the occlusions. A preferred application is the removal of blood clots (thrombi and emboli) from small cerebral vessels to reverse the effects of an ischemic stroke. The operating parameters and techniques are chosen to minimize the amount of heating of the fragile cerebral vessel walls occurring during this photoacoustic treatment. One such technique is the optical monitoring of the existence of hydrodynamic flow generating vapor bubbles when they are expected to occur and stopping the heat generating pulses propagated along an optical fiber that is not generating such bubbles.

A method for qualifying airfoil blades includes securing an airfoil blade into a fixture, taking digital measurements of the airfoil blade, comparing the digital measurements of the airfoil blade with measurements of a target model, calculating deviations between the digital measurements of the airfoil blade and the measurements of the target model, determining a required treatment for the airfoil blade to conform with the measurements of the target model, directing a reworking system to provide the required treatment to the airfoil blade, and repeating the previous steps until it is determined that no further treatment is required. An airfoil qualification system for performing the method for qualifying airfoil blades includes a measurement station, a data processing system in communication with the measurement station and for determining a point deviation from a surface standard point for each of at least a portion of the plurality of surface points and for determining a required treatment of the airfoil, and a reworking station for directing treatments to the airfoil in response to input from the data processing system.

A method for direct therapeutic treatment of myocardial tissue in a localized region of a heart having a pathological condition. The method includes identifying a target region of the myocardium and applying material directly and substantially only to at least a portion of the myocardial tissue of the target region through transseptal delivery. The material applied results in a physically modification the mechanical properties, including stiffness, of said tissue. Various devices and modes of practicing the method are disclosed for stiffening, restraining and constraining myocardial tissue for the treatment of conditions including myocardial infarction or mitral valve regurgitation. The novel treatment may be combined with prior art diagnostic and therapeutic techniques employing transseptal delivery methods.

A pneumostoma management system includes a pneumostoma management device for maintaining the patency of a pneumostoma and a drug delivery device for pneumostoma care. The drug delivery device includes a therapeutic agent dispenser for supplying a therapeutic agent and a propellant at positive pressure, a tube for entering the pneumostoma and a limiting device for limiting the depth of insertion of the tube into a pneumostoma. The drug delivery device may be used to introduce therapeutic agents into the pneumostoma for direct treatment of the pneumostoma, treatment of the lung by way of collateral ventilation, and / or treatment of non-lung tissues by diffusion into the bloodstream.

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and / or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

A pneumostoma management system includes a pneumostoma management device for maintaining the patency of a pneumostoma and a drug delivery device for pneumostoma care. The drug delivery device may be used to introduce therapeutic agents into the pneumostoma for direct treatment of the pneumostoma, treatment of the lung by way of collateral ventilation, and / or treatment of non-lung tissues by diffusion into the bloodstream. The drug delivery device includes a therapeutic agent dispenser for supplying a therapeutic agent and a propellant at positive pressure, an outlet and a connector for correctly positioning the outlet relative to a pneumostoma management device. The drug delivery device includes a self-centering and self-sealing connector for engaging the pneumostoma management device.

Systems, devices, and methods for treating a glaucomatous eye are provided. Embodiments may provide a treatment probe for treating an eye of a patient. The treatment probe may have an elongate body with a contact surface at a distal end of the elongate body. A treatment fiber or light source may be housed in the treatment probe and may be configured to direct treatment energy from the contact surface. The contact surface may be configured to couple to a surface of the eye to deliver the energy into the target area. In many embodiments the contact surface may have a convex configuration with a rounded outer shape and edge that facilitates the sweeping of the probe surface across the eye during treatment delivery. In some embodiments the probe may be swept in arc motions while delivering treatment energy to the eye.

Incontinence systems and methods for directing treatment to a target tissue of a patient comprise a guide having a first palpation member and a probe body having a treatment zone and a second palpation member. The guide is configured to be inserted into a urethra of the patient. The first palpation member is positioned in a fixed relationship to an anatomical landmark, such as a bladder neck. The probe body is configured to be inserted into a vagina of the patient. The second palpation member is registered proximal the first palpation member so as to position the treatment zone of the probe adjacent the target tissue of the patient and away from the nerves and / or tissues in the area of the bladder neck and bladder.

Embodiments relate to systems and methods for delivery of oxygen or other treatment gases to a patient without requiring physical contact or enclosure of the patient. Embodiments can include a delivery hood, sensing components, and a gas distribution system including one or more gas delivery ports. Gas delivery ports may be individually controlled based on input from the sensing components to alter the volume and orientation of treatment gas flow directed at a patient. Sensing components can include cameras or other sensors that detect the position of a patient's head, and gas delivery ports may then be controlled to direct treatment gas flow in the direction of the patient's head. Embodiments and methods described thereby allow for efficient oxygen or other gas delivery to a patient without requiring contact or enclosure of the patient.

An electro diagnostic functional assessment unit (EFA-2) that diagnoses age of and treats soft tissue injuries. The EFA-2 utilizes sensor(s) including EMG, Range of Motion, FCE, pinch and grip, and allows for monitoring of muscles and muscle groups to ascertain compliance, pain and function. The EFA-2 also monitors disc pathology and determines whether a person requires surgery or conservative care and, the age of the disc. Additionally, the EFA-2 monitors EEK activity and NCV, as well as invasive EMG that monitors nerve damage. Previously, with NCV the temperature and the position of electrodes would effect readings and produce false positive or false negative readings. The EFA-2 eliminates these problems by incorporating temperature sensor(s) and electrode placement sensor(s). The EFA-2 also provides direct treatment by means of ultrasound and electrical stimulation. Thus, the EFA-2 allows diagnosis any treatment by means of a single unit.

The invention provides an economic and efficient dephosphorization method, comprising the steps of microfiltration and ion exchange. In the method, (1) phosphoric sewage is filtered by a microfiltration membrane to intercept and remove suspended matters, bacteria and colloid substances larger than 0.1micron, produced water subjected to pretreatment is lead to an ion exchange column, phosphorus in the sewage is adsorbed by a dephosphorization adsorbent, and the produced water is finally lead to a clear water tank; and (2) the saturated dephosphorization adsorbent is regenerated by suing a sodium hydroxide solution, and an eluent is condensed and separated through an evaporator. In the invention, an organic polymer microfiltration membrane or an inorganic microfiltration membrane is adopted, and the dephosphorization adsorbent is filled in the ion exchange column; and the bore diameter of the microfiltration membrane is 0.05-10 mum, the porosity of the microfiltration membrane is 30-95%, and a membrane assembly is of a plate type, or a tube type, or a roll type or a hollow fiber type. The invention is used for the direct treatment of the phosphorus sewage or the advanced treatment of the phosphorus sewage treated by a biological method so as to ensure that the phosphorus content of the final produced water is lower than 0.5mg / L and avoid excessive phosphorus discharged into a water body to result in eutrophication, and meanwhile, the ion exchange eluent containing high-content phosphorus is further condensed and separated to achieve the purpose of recycling the sewage.

It is demonstrated in the present invention that G-quadruplex ligands can be used to both shorten telomeres and inhibit telomerase by causing telomere uncapping. The invention relates to compositions and methods of treating cancer stem cells comprising the administration of G-quadruplex ligands, such as 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4), which can effectively inhibit or reduce the growth of cancer stem cells. The invention also relates to a synergistic effect in inhibiting or reducing the growth cancer stem cells when a G-quadruplex ligand is combined with a mitotic spindle poison, such as paclitaxel, or other agents used in the treatment of cancer and disease. The invention also relates to RHPS4 inducing non-cancerous cell and non-cancerous stem cell proliferation.

The invention discloses a treatment method for waste incineration power plant leachate and a device thereof. The waste leachate is put into a raw water regulation pool, a coagulation reaction system, a first-stage UBF reactor, a first-stage UBF reactor effluent middle pool, a second-stage UBF reactor, a second-stage UBF reactor effluent middle pool, a denitrification pool, a nitration pool, a built-in MBR system, and a nanofiltration system for processing. According to the invention, the UBF reactor effluent middle pools are arranged behind the UBF reactors for mud-water separation and backflow after the UBF reactor effluent, guaranteeing the mud concentration in the UBF reactors and treatment effeciency. Using a built-in MBR membrane module placed in a biochemical pool helps to reduce floor space and lower energy consumption. The use of physical and chemical, biochemical, and membrane filtration technology association for the direct treatment of waste leachate can reach recycling with zero emission.

Process of obtaining lycopene. The present invention relates to a new process of obtaining carotenoids, especially lycopene, starting from natural biosynthesis sources in general and, specifically, from submerged cultures of mucorales fungi such as Blakeslea, Choanephora or Phycomyces. The process described makes it possible to simplify the recovery process and obtain an increase in purity of the product. It comprises the following steps: 1) Direct treatment with alcohol on the natural source of biosynthesis (fermentation medium for example) and separation of a wet, purified biomass. 2) Conditioning of the purified biomass by drying plus disintegration or breakdown of the same. 3) Solid-liquid extraction of the lycopene with an organic solvent. 4) Concentration of the enriched extract. 5) Precipitation / crystallization by addition of alcohol. 6) Filtration. 7) Dryingin

The invention discloses a short-range cluster cancellation method for airborne non-side-looking array radar. The method includes: estimating pitching angle corresponding to a short-range fuzzy distance door, estimating short-range clutters according to prior information of spatial-temporal clutter spectrum, and subjecting the original received data to short-range clutter cancellation. Short-range clutters can be suppressed effectively by the method, and cluster suppression performance better than direct treatment is obtained. Results of simulation experiments proof that the method is effective.

An electro diagnostic functional assessment unit (EFA-2) that diagnoses age of and treats soft tissue injuries. The EFA-2 utilizes sensor(s) including EMG, Range of Motion, FCE, pinch and grip, and allows for monitoring of muscles and muscle groups to ascertain compliance, pain and function. The EFA-2 also monitors disc pathology and determines whether a person requires surgery or conservative care and, the age of the disc. Additionally, the EFA-2 monitors EEK activity and NCV, as well as invasive EMG that monitors nerve damage. Previously, with NCV the temperature and the position of electrodes would effect readings and produce false positive or false negative readings. The EFA-2 eliminates these problems by incorporating temperature sensor(s) and electrode placement sensor(s). The EFA-2 also provides direct treatment by means of ultrasound and electrical stimulation. Thus, the EFA-2 allows diagnosis any treatment by means of a single unit.

The invention relates to a multilayer bionic intestinal stent for treating intestinal diseases, belongs to biological medical textiles, and aims to overcome the defects that traditional metal intestinal stent is high in stress, causes intestinal tract secondary damage, cannot be directly used for treating intestinal diseased parts, and the like. The stent comprise at least three layers, the innermost layer 1 is a smooth medical polymer coating 0.05-0.25mm in thickness, the middle layer 2 is the tubular tent body, which is knitted and woven by medical polymer, with radial compression force of 30-240cN and a seamless tube wall structure, and the outermost layer 3 is a medicine film layer for treating the diseased parts. The stent has the advantages that the stent is excellent in mechanical performance and capable of realizing non-degradation, partial degradation and total degradation, degradation time is controllable, the pharmaceutical formulation of the outer layer is adjusted, and a mechanical model is built to allow the support force of the stent to be controllable.

The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

Macrophages sequester and aggregate ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) in their lysosomes. The amount of USPIO loading of macrophages depends upon the route and dose of administration, and the pharmacokinetics of accumulation and removal. Both fixed macrophages and activated macrophages associated with inflammatory diseases and cancer phagocytize USPIOs, and the loaded macrophages can serve to identify the extent of a macrophage-dependent disease as well as to direct treatment options. Furthermore, the absorption of energy from incident electromagnetic waves by the aggregated nanoparticles can be used for conformal thermotherapy. The USPIOs can further be used to carry drugs to the same activated macrophages. The co-administered drugs can be bound to the USPIO by condition-dependent releasing links that are responsive to local pH or heating.

The present invention relates to a traditional Chinese medicine preparation, in particular to a traditional Chinese medicine liquid for treating beriberi and the preparation method. The present invention uses 11 traditional Chinese medicines of Mongolian dandelion herb, lightyellow sophora root, dahurian patrinia herb, sessile stemona root, amur corktree bark, baical skullcap root, Szechuan pepper, belvedere fruit, divaricate saposhnikovia root, flos caryophyllata, castor bean and so on according to certain mix ratio, and the medicine liquid is prepared by boiling for 2 times, filtering and merging the filtrate. The traditional Chinese medicine liquid for treating beriberi of the present invention is based on the principle of external therapy of traditional Chinese medicine and external fumigating and washing method. The present invention prepares a pure traditional Chinese preparation scientifically, which can stimulate the pores and the points at the same time of immersing feet and carry out the direct treatment on the affected area, thus improving the blood circulation, stopping pain, relieving swelling, anti-erosion, generating muscle, removing odor and eliminating disease, and achieving the goal of curing the beriberi and tinea pedis.

The invention relates to proton exchanging film fuel cell membrane electrode platinum loading analysis, concretely to a measuring method for proton exchanging film fuel cell membrane electrode platinum loading. The method includes steps: 1) accurately measuring size and quality of a MEA sample, heating the MEA sample to adequately incinerate carbon in the MEA sample, after cooling, adding thick sulfuric acid and thick nitric acid to the sample, and heating solution to completely dissolve platinum; 2) adding water to scale to prepare measured sample solution; 3) measuring platinum content in the solution by inductance coupling plasma atom emission spectroscopy method, calculating membrane electrode platinum loading in MEA sample. The invention obtains measured sample by an MEA direct treatment method, uses an ICP-AES analysis method which has high sensitivity, high accuracy, fast process, simple operation and good feasibility to measure platinum content, and estimates MEA which is key material of PEMFC.

An isotope production system, emanation generator, and process are disclosed for production of high-purity radioisotopes. In one implementation example, high-purity Pb-212 and / or Bi-212 isotopes are produced suitable for therapeutic applications. In one embodiment the process includes transporting gaseous radon-220 from a radium-224 bearing generator which provides gas-phase separation of the Rn-220 from the Ra-224 in the generator. Subsequent decay of the captured Rn-220 accumulates high-purity Pb-212 and / or Bi-212 isotopes suitable for direct therapeutic applications. Other high-purity product isotopes may also be prepared.

The present invention can eliminate the multipath effect, channel interference and Doppler effect in mobile communication. The reception method includes the direct treatment of the received RF baseband signal with filter, multiplier and preset data and the direct feeding of the treated signal to the software adjudication decoder. The RAKE receiver of the present invention consists of matching filter, delay search tracker, predicting filter, smoothing filter, delay regulator, multiplier, multipath adder, filter parameter data base, S / N measuring comparator and one-out-of-three selector.

The invention discloses a method for treating nondegradable organic wastewater by oxidation by using a transition metal catalyst, which comprises the following steps: regulating the pH value of wastewater to 3-7, sending the wastewater into a three-phase reactor, adding a transition metal catalyst accounting for 0.001-0.01 wt% of the wastewater, stirring, introducing compressed air as an oxidant according to the air-water ratio of 5-20, reacting for 0.5-2 hours, carrying out coagulative precipitation on the effluent water, and discharging after reaching the standard or sending into a secondary biochemical tank for treatment. The transition metal catalyst is a compound of two or more simple substances or oxides of iron, manganese, copper, silver, nickel and cobalt. The invention can be used as a direct treatment method or pretreatment method for nondegradable organic wastewater, enhances the biodegradability of the wastewater, and is beneficial to subsequent biochemical reaction. Compared with the common nondegradable organic wastewater treatment method, the invention has the advantages of milder reaction conditions, quantitative catalyst addition, lower catalyst consumption, shorter retention time, cheaper oxidant and lower treatment cost.